YLYue Liu

Yue Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yue Liu has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Jinjie He

    Department of Colorectal Surgery and Oncology (Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education), The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

    2 shared publications
  • Kefeng Ding

    Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    2 shared publications
  • Ying Yuan

    Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China

    2 shared publications
  • Chengcheng Liu

    Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

    1 shared publication
  • Chuansheng Guo

    Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention China National Ministry of Education) The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China

    1 shared publication
  • Dong Xu

    Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Low SLC8A1 in Colorectal Cancer Dictates Radiotherapy Resistance Through Calcium‐Dependent ANXA2 + sEVs Driving M2 Polarization of TAMs

    by Yimin Fang, Jinghan Zhu, Qian Xiao, Qichun Wei, Xiujing He, Ping Li, Kai Jiang, Yue Liu, Yeting Hu, Weiwei Yu, et al.

    Background and Aims: Tumors actively remodel the tumor microenvironment (TME) to foster therapy resistance. However, the underlying mechanisms remain poorly defined. This study aims to characterize how colorectal cancer (CRC) cells drive TME remodeling to promote radioresistance. Methods: A radioresistant CRC cell line was established via serial in vivo irradiation. Single‐cell RNA sequencing characterized TME alterations. The role of tumor‐derived small extracellular vesicles (sEVs) in macrophage polarization was assessed. Proteomic analysis identified ANXA2 as a key sEVs cargo, and calcium‐dependent sEV secretion was investigated through SLC8A1 modulation. Clinical relevance analyses were further assessed. Results: The radioresistant model exhibited enhanced treatment resistance to irradiation and increased infiltration of M2‐like tumor‐associated macrophages (TAMs), while TAM depletion restored radiosensitivity. Tumor‐derived sEVs promoted M2 polarization by activating STAT6 phosphorylation, with ANXA2 as the key functional cargo. Further analysis revealed that SLC8A1 deficiency increased intracellular Ca 2 + levels, boosting secretion of ANXA2 + sEVs and subsequent TAM M2 polarization. Clinically, low SLC8A1 expression correlated with higher M2 TAM infiltration, poorer therapeutic response, and worse survival outcomes in CRC patients. Conclusion: CRC cells with low SLC8A1 expression remodel the TME to foster radioresistance via calcium‐dependent secretion of ANXA2 + sEVs and subsequent M2 polarization of TAMs.

  • Open Access

    Circulating tumor DNA as a prognostic biomarker in metastatic colorectal cancer: Post-hoc analysis of treatment response and survival outcomes in the ALTER-C-002 study

    by Yue Liu, Jin-Jie He, Sheng Chen, Yun-Jie Song, Jin-Lin Du, Yu-Ping Zhu, Dong-Sheng Chen, Wang-Long Deng, Ying Yuan, Ke-Feng Ding

    Circulating tumor DNA (ctDNA) derived from blood samples can serve as a minimally invasive, real-time indicator of tumor burden and treatment response in metastatic colorectal cancer. This study evaluated the association between baseline ctDNA levels and changes in ctDNA during treatment with response and survival outcomes in the phase II ALTER-C-002 trial, which investigated first-line anlotinib combined with capecitabine and oxaliplatin in patients with rat sarcoma (RAS) and B-Raf proto-oncogene (BRAF) wild-type metastatic colorectal cancer. In this post-hoc biomarker analysis, plasma samples were collected at baseline, near the best radiologic response (C1), and at the timepoint closest to disease progression or last follow-up (C2). These samples were analyzed using a 90-gene next-generation sequencing (NGS) panel, with ctDNA abundance quantified as maximum somatic allele frequency (MSAF), where MSAF <0.001 indicated ctDNA negativity. Biomarker data were obtained for 26 patients, 25 of whom had measurements at all three timepoints. Notably, baseline MSAF was higher in patients with liver-only metastasis (p=0.017). MSAF decreased significantly at C1 compared to baseline (p<0.001) and increased at C2 relative to C1 in patients exhibiting progressive disease (PD) (p<0.001); additionally, higher MSAF at C1 was associated with subsequent PD at C2 (p=0.015). All patients who tested ctDNA-negative at C1 achieved an objective response, and ctDNA negativity at this timepoint correlated with longer progression-free survival (PFS) (p=0.012) and overall survival (OS) (p=0.006) compared to ctDNA-positive patients. Furthermore, KRAS/BRAF mutations detected in ctDNA were linked to shorter PFS and OS (all p<0.05). In conclusion, baseline ctDNA burden and early ctDNA clearance may function as prognostic and on-treatment biomarkers of therapeutic efficacy in metastatic colorectal cancer, warranting prospective validation.

  • Open Access

    A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol

    by Jinjie He, Yue Liu, Chengcheng Liu, Hanguang Hu, Lifeng Sun, Dong Xu, Jun Li, Junye Wang, Xiaobing Chen, Rongbo Lin, et al.

    Background: Chemotherapy combined with antivascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor monoclonal antibodies is the most promising approach to prolong survival and improve the quality of life of patients with unresectable metastatic colorectal cancer (mCRC). Anlotinib is an oral antiangiogenic tyrosine kinase inhibitor that targets VEGF receptors 1/2/3, fibroblast growth factor receptors 1-4, and platelet-derived growth factor receptors a/β. Since anlotinib combined with oxaliplatin and capecitabine (CAPEOX) as a first-line treatment was previously shown to be effective and safe for patients with RAS/BRAF wild-type (WT) mCRC, we designed this randomized, open-label, parallel-group, non-inferiority, phase III study to evaluate the efficacy and safety of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX in patients with RAS/BRAF WT mCRC. Methods/design: The primary inclusion criteria are Eastern Cooperative Oncology Group performance status 0/1, confirmed RAS/BRAF WT colorectal adenocarcinoma, and unresectable metastases assessed by a multidisciplinary team. The main exclusion criteria are as follows: high microsatellite instability or deficient mismatch repair status, resectable or potentially resectable metastases, and previous systemic therapy for mCRC. A total of 698 patients will be randomized into the anlotinib and bevacizumab groups in a 1:1 ratio. Patients will receive 4 to 8 cycles of induction therapy (CAPEOX plus anlotinib or bevacizumab), followed by maintenance treatment (capecitabine plus anlotinib or bevacizumab) until disease progression or unacceptable toxicity. Progression-free survival (PFS) assessed by an independent review committee is the primary endpoint, whereas investigator-assessed PFS, overall survival, objective response rate, disease control rate, duration of response, resection rate of liver metastases, quality of life, and safety are the secondary endpoints. Enrollment commenced in May 2021. Discussion: A prospective, randomized, phase III trial will provide a meaningful comparison of the efficacy and safety of anlotinib plus CAPEOX with standard treatment for patients with unresectable RAS/BRAF WT mCRC.